14-12-2011 20:22 Human tissue cells derived from induced pluripotent stem (iPS) cells recapitulate many of the characteristics and functionality expected of in vivo cell types. iCell® Cardiomyocytes are derived from human IPS cells and are currently being used in both drug discovery and basic research in Industrial and Academic settings. Dr. Eric Chiao of Hoffmann-La Roche Inc. (Roche) will lead this presentation and provide data showing the characterization and utility of iCell Cardiomyocytes, how they are being used in drug development, and how they are increasing our understanding of basic human cardiomyocyte cellular biology.

Read more:
Utilizing Stem Cell-derived Cardiomyocytes for Early Safety Screening - Webinar Presentation - Video

Recommendation and review posted by sam

29-01-2012 18:01 Biomarkers in Depression, Anxiety and ADHD

View original post here:
Dr Evian Gordon - World Conference on Personalized Medicine 2012 (15 Minutes).mp4 - Video

Recommendation and review posted by sam

01-02-2012 14:27 Theral Timpson, Host and Producer at Mendelspod.com shares his thoughts about the Personalized Medicine World Conference 2012 (PMWC2012), which was held in Mountain CA, USA (January 2012). The interview covers the company competition conducted during the PMWC2012 and discusses the winner of the 2012 First Prize - Auxogyn. Please leave your comments and questions on this page.

Here is the original post:
Review of the Personalized Medicine World Conference 2012 - Video

Recommendation and review posted by sam

Enlarge image Siemens Signs First Personalized Medicine Diagnostics Deals

Guenter Schiffmann/Bloomberg

A sign sits on a wall outside the entrance to Siemens AG's headquarters in Munich.

A sign sits on a wall outside the entrance to Siemens AG's headquarters in Munich. Photographer: Guenter Schiffmann/Bloomberg

Siemens AG, Europe’s largest engineering company, is wading into the multibillion-dollar field of personalized medicine by announcing deals to develop companion tests with two drugmakers.

The Munich-based company will work with HIV drugmaker ViiV Healthcare Ltd. and Tocagen Inc., a developer of an experimental brain tumor treatment, to create tests that will determine which patients will benefit from the therapies, said Trevor Hawkins, head of Siemens’ next generation diagnostics division.

“This is a major step forward for us, moving into this multibillion market, which we haven’t been in up until today,” Hawkins said in an interview. “We have every expectation to now growth this much further beyond where we are.”

Personalized medicine involves determining whether a patient is genetically susceptible to a particular disease or would be especially responsive to certain treatments. These new therapies often require special genetic tests, which are being created by separate companies, in some cases.

Siemens, which makes products ranging from light bulbs to high-speed trains, is under increased pressure to keep up with competitors such as Basel, Switzerland-based Roche AG, which is attempting a hostile takeover of gene-mapping company Illumina Inc., Ben Uglow, an analyst at Morgan Stanley, wrote in a note to clients last month.

Molecular Diagnostics

The market for molecular diagnostics, which includes personalized medicine tests, will more than double in the U.S. to $5.5 billion in 2016 from its $2.5 billion size in 2010, according to TriMarkPublications.com.

ViiV, a venture between London-based GlaxoSmithKline Plc (GSK) and New York-based Pfizer Inc. (PFE), the world’s biggest drugmaker, has an HIV drug called Selzentry that works with patients that have a specific form of the virus. Siemens will develop a test to help doctors determine which patients would benefit from the therapy.

Tocagen, based in San Diego, is working on a treatment for glioma, or brain cancer, called Toca 511 that’s in early human trials. Working with Siemens will give the company more credibility in discussions with the Food and Drug Administration and a quicker approach in marketing if approved, said Harry Gruber, chief executive officer of closely held Tocagen.

Formal Process

“We realized you really have to have a company that could commercialize as part of your team during the registration studies,” Gruber said in an interview. “We went through a very formal process to interview all the major players in the companion diagnostics space, and from the very beginning, this is the team we jelled with.”

No financial details of the agreements were disclosed.

Siemens, Roche and Abbott Laboratories (ABT) are seeking to form partnerships with drugmakers to develop these companion tests, said David Parker, vice president of the consulting firm Boston Healthcare.

“The test makers are all out there talking with potential pharma partners,” Parker, based in Washington, said in an interview. “I think we’re going to see nothing but an increase in the frequency in which drugs and diagnostics come to market.”

The pace of such approvals has accelerated, said Gwen Gordon, a spokeswoman for the Personalized Medicine Coalition, an industry advocacy group based in Washington. More than 72 such therapies are available today, a fivefold increase from the 13 available in 2006.

“In the past, it had been a much more difficult process to get the drug and the diagnostic approved, because there’s different people at the FDA that work on each set of products,” Gordon said. Now, the groups are coordinating more as drugmakers recognize the market’s potential. “They recognized that there is a market for tailored therapies for patients that know that the drug is going to work.”

To contact the reporter on this story: Ryan Flinn in San Francisco at rflinn@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Read the original here:
Siemens Signs First Agreements for Personalized Medicine Diagnostics

Recommendation and review posted by sam

27-12-2011 11:44 Spinal cord injury treatment. http://www.projectwalk.org exists to provide an improved quality of life for people with spinal cord injuries through intense exercise-based recovery programs, education, support and encouragement.

Go here to read the rest:
"Lori Hammond", "Project Walk Spinal Cord Injury Recovery" - Video

Recommendation and review posted by sam

01-02-2012 16:34 Spinal cord injury treatment. http://www.projectwalk.org exists to provide an improved quality of life for people with spinal cord injuries through intense exercise-based recovery programs, education, support and encouragement.

Continued here:
"Kyle Eade, "Project Walk Spinal Cord Injury Recovery" - Video

Recommendation and review posted by sam

A BRIGHT man suffered a spinal cord injury that paralysed both his legs after being stabbed in the lower back during a fight between two families, the County Court at Wangaratta has heard.

Shannon Larry Orcher, 20, is on trial, accused of stabbing Daniel Robinson three times and his father Alan Robinson seven times, in the early hours of October 4, 2009.

Orcher’s lawyer says his client acted in self-defence in attacking the pair, while prosecutors insist the Eurobin man intentionally set out to seriously injure the two men.

A 13-person jury was empanelled for the trial yesterday morning and given an outline of the facts of the case by prosecutor David O’Doherty.

He told the court Orcher and his brother Cheyne Orcher had visited the Robinson home after they left the Alpine Hotel in Bright when it closed at 1am.

Orcher allegedly told a friend of the Robinsons, Mathew Walsh, he was going to “bash” Daniel Robinson and have sex with his sister, Jessica Robinson.

At 3am, the Robinson siblings had arrived at their Cobden Street home after their night out at the same hotel when Daniel Robinson said he heard footsteps coming down the driveway and the Orcher brothers yelling they were

going to kill him, rape his

sister and burn down the house.

Mr Robinson woke up his father and the pair said they went out in a car to find the Orchers “to talk to them and calm the situation down”.

But the court heard yesterday the Robinsons were met with aggression and verbal abuse when they met Shannon Orcher, his brother and another relative in the driveway of the Orcher brothers’ home.

Police said a fight broke out between the men, both inside and outside the house.

They allege Orcher stabbed Alan Robinson seven times in the back and shoulders in the bedroom of the house, before stomping on his face and choking him to the point that he started to lose consciousness.

Orcher is alleged to have then walked out of the house and stabbed Daniel Robinson in the lower back three times, causing immediate paralysis to both his legs.

Police say the accused then left the scene and went to Beau Orcher’s Coronation Avenue unit, where he hid the knife, took off his blood-stained shirt and washed blood off his arms.

He later showed to police the shirt and knife, which he had hidden under a mattress in a couch, and admitted to stabbing both Robinson men, although he said they were both inside his house at the time of the stabbing.

Orcher told police he “lost it” and “I didn’t mean to ... do so much but I tried to stop them”.

The court heard both Robinson men had been armed, the father with a piece of a broom handle and the son with a cricket bat but the Orcher men didn’t report receiving any injuries in the incident.

Orcher’s lawyer said his client injured the Robinson men “to stop them” — an act of self-defence.

Read more from the original source:
Dad, son injured in stabbing frenzy

Recommendation and review posted by sam

07-11-2011 15:39 http://www.StemCellTreatment.org Salima had stem cell treatment for Fibromyalgia and had very good results. We have had great success with stem cell therapy for Fibromyalgia also known as FMS. Fibromyalgia symptoms include pain and tenderness in the joints, muscles and other soft tissue. Stem cell treatment for fibromyalgia is something that ASCAAC specializes in. Go to our website for more information and fill out the form or give us a call so we can answer your stem cell and fibromyalgia questions!

Read this article:
Stem Cell Treatment Fibromyalgia - Video

Recommendation and review posted by Bethany Smith

20-12-2011 09:01 If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.

See more here:
Adult Stem Cell Treatments for COPD -Real patient results, USA Stem Cells- Donald W. Testimonial - Video

Recommendation and review posted by Bethany Smith

10-01-2012 17:54 Cell-based therapy research at Swedish Heart and Vascular Institute is quintessential to medical advancement. Medical director Dr. Paul P. Huang researches stem cell therapy pertaining to cardiovascular disease. He provides an historical perspective of stem cell research and explains how stem cells can help cardiovascular patients avoid surgery and improve their quality of life. Dr. Huang believes that regenerative medicine is medicine's next frontier. For more information visit http://www.swedish.org

Read more from the original source:
Cell-based Therapy Research - Video

Recommendation and review posted by Bethany Smith

12-01-2012 07:24 If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.

Here is the original post:
Adult Stem Cell Treatments for COPD -Real patient results, USA Stem Cells- Leon B. Testimonial - Video

Recommendation and review posted by Bethany Smith

SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire -02/06/12)- Benitec Biopharma (ASX: BLT.AX - News) and Medistem (Pinksheets: MEDS.PK - News) announced today the successful treatment of rheumatoid arthritis in preclinical models using Benitec Biopharma's patented gene silencing technology applied to stem cell-derived immune system cells called dendritic cells. The studies, which were led by Dr. Wei-Ping Min of the University of Western Ontario, were published in the "Journal of Translational Medicine" on the 31st January 2012(1). Benitec Biopharma's CEO Dr Peter French and Medistem's scientist Dr Rosalia De Nochea Champion were co-authors on the paper.

"In 2003, Dr Wei-Ping Min's group, together with Medistem's CEO Dr Thomas Ichim, were the first to apply the technology of RNA Interference to the immune system, by silencing the autoimmune disease-associated gene IL-12p35(2)," said Dr. Peter French. "In the current paper, Dr. Min expanded these studies to a disease-relevant model, and using stem cell-derived dendritic cells was capable of developing promising preclinical data relevant to rheumatoid arthritis."

By specifically "silencing" various genes, Benitec Biopharma's ddRNAi technology is capable of modulating stem cells outside of the body, in order to endow them with new desired therapeutic activities. The first clinical study which combined stem cell therapy with Benitec Biopharma's ddRNAi technology was in a trial of AIDS-related lymphoma patients, the results of which were published in 2010 and showed the safety and feasibility of the approach(3).

In the current paper, ddRNAi was used to generate dendritic cells that acted as a "tolerogenic vaccine," which specifically blocked the pathological immune response in rheumatoid arthritis, without blocking healthy immune responses. It is contemplated that by blocking pathological immunity, ddRNAi-modified stem cell-based therapies, such as those being developed by Medistem, could provide novel treatment and curative approaches to tissue that has been damaged. In the case of rheumatoid arthritis the tissue would be cartilage and synovium.

"Medistem is the first company to take a stem cell from discovery to clinical trials in the short span of four years," said Dr. Weiping Min. "This is a unique example of merging basic research, as performed in my laboratory with the translational expertise of Dr. Ichim's company."

Medistem has previously published work in the area of rheumatoid arthritis, however the company's main efforts are currently focused on heart failure, for which it has started the RECOVER-ERC 60 patient double blind, dose escalating, placebo controlled trial using its Endometrial Regenerative Cell (ERC) universal donor stem cell. The company also has a critical limb ischemia trial recently approved by the FDA.

"In our opinion the Benitec Biopharma technology platform is the only means of inducing the stable expression of gene silencing in a stem cell," said Dr. Ichim, CEO of Medistem. "Given that Benitec Biopharma has pioneered ddRNAi for human therapy, and has been involved in applying it to stem cell manipulation, we are eager to continue our collaborations and finding means of leveraging the unique properties of the ERCs with the transformational technology of ddRNAi to develop novel cell therapies for a range of chronic life-threatening human diseases."

"Benitec Biopharma and Medistem are in discussions as to how to advance this work both in rheumatoid arthritis and in a range of other disease states that would lend themselves to such a novel combination therapy," Dr. French added.

About Medistem
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia and heart failure. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf.

Cautionary Statement This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

About Benitec Biopharma

Benitec Biopharma Ltd is developing novel treatments for chronic and life-threatening conditions based on targeted gene-silencing activity using a transformational technology: DNA-directed RNA interference (ddRNAi) -- sometimes called expressed RNAi. The technology's potential to address unmet medical needs and to cure disease results from its demonstrated ability to permanently silence genes which cause the condition. Importantly, this technology's target gene and related gene pathways will rarely have presented as a therapeutic avenue for research for the traditional small molecule agents, currently accounting for the majority of today's pharmaceutical products.

Benitec now either owns or exclusively licenses from CSIRO more than 40 granted or allowed patents in the field of RNA interference for human therapeutic applications. Patents have been granted in key territories such as the USA, the UK, Japan, Europe, Canada and Australia. In addition, Benitec has almost 50 patent applications pending for which it is the owner or exclusive licensee from CSIRO, and has further intellectual property under development as a result of its pipeline program.

Founded in 1997 and trading publicly since 2001, Benitec Biopharma is listed on the Australian Securities Exchange (ASX) under the symbol "BLT." Benitec aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. In addition to its focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, Benitec Biopharma is pursuing programs with licensees.

References
(1) Li, R et al. Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. "Journal of Translational Medicine" 2012, 10:19 doi:10.1186/1479-5876-10-19.
(2) Hill JA et al. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. "The Journal of Immunology," 2003, 171: 691-696.
(3) DiGiusto DL et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34+ cells in patients undergoing transplantation for AIDS-Related Lymphoma. "Science Translational Medicine," 2(36): 36ra43.

Original post:
Benitec Biopharma and Medistem Technologies Successfully Combined in Preclinical Stem Cell Therapy for Rheumatoid ...

Recommendation and review posted by Bethany Smith

Their sophisticated data-filtering strategy, which uses gene expression during normal development as a starting point, offers a new, efficient and potentially game-changing approach to gene discovery.

Babies born with CDH—representing one in every 3,000 live births—have a hole in the diaphragm that separates the abdominal cavity from the chest cavity, and may die due to poor growth of the lung.

Patricia K. Donahoe, M.D., director of the Pediatric Surgical Research Laboratories at MGHfC, explained, "That hole can be fixed surgically if CDH has been diagnosed in time. But even surgery does not rescue the infants' impaired lung development, which often leads to fatal respiratory complications." Patients who survive into adulthood "tend to have a lot of ongoing health issues," she noted.

Donahoe and her colleagues Meaghan Russell, Ph.D., and Mauro Longoni, M.D., and Jackson Laboratory Professor Carol J. Bult, Ph.D., a computational biologist, led the research, published in the Proceedings of the National Academy of Sciences. The team had two goals: to identify the genes and gene networks that cause the hole in the diaphragm in order to develop new diagnostics and preventive treatments, and to learn more about how healthy lungs form to boost lung development in post-operative infant patients.

Bult and her Jackson colleague Julie Wells, Ph.D., generated gene expression profiles—snapshots of gene activity—for embryonic mouse diaphragms at multiple stages of development. Using algorithms designed by the JAX-MGH team, they used these data to then predict genes likely to contribute to diaphragm defects.

Bult said, "We asked which genes in our developmental data sets work together in common pathways, and which of these pathways contain previously known CDH genes from human studies and mouse models?"

To build gene networks, the researchers used the Mouse Genome Informatics (MGI) data base resource based at The Jackson Laboratory. MGI, freely available to the research community, maintains the most comprehensive collection of mouse genetic and genomic information.

The researchers' filtering strategy identified 27 new candidate genes for CDH. When the investigators examined the diaphragms of knockout mice for one of these candidate genes—pre-B cell leukemia transcription factor 1 or Pbx1—they found previously unreported diaphragmatic defects, confirming the prediction.

The next step in the project is to screen patients for mutations in Pbx1 using the collection of CDH patient data and DNA that MGHfC and Children's Hospital Boston have been accumulating for years in collaboration with hospitals from around the world.

The research reported in the paper opens the door "not only to further research to explore the effects of the other 26 CDH candidate genes," Bult said, "but to a disease gene identification and prioritization strategy for CDH, an approach that can be extended to other diseases and developmental anomalies."

Provided by Jackson Laboratory

Go here to see the original:
Researchers find clues to common birth defect in gene expression data

Recommendation and review posted by Bethany Smith

18-12-2011 05:11 "By chance, the light-skinned coloured fish that I used for that research also taught us a lot about how Europeans, how humans became lighter skinned ... what Professor Cheng discovered was perhaps one of the most important genetic mutations ever found. A single change among literally billions of coded instructions within Zebrafish DNA that reduced black pigment from their stripes... Soon after this, identical genetic mutation was found in fair-skinned Europeans ... not only did white-skinned people evolve from black-skinned people, but lighter-skinned people, whether they're European, or whether they're Asian, ... we're actually mutants, of the dark-skinned people..." Nina Jablonski breaks the illusion of skin color http://www.ted.com Always Revealing, Human Skin Is an Anthropologist's Map http://www.nytimes.com

Read this article:
6/7 Skin Deep - white-skinned people evolved from black-skinned people - Video

Recommendation and review posted by Bethany Smith

09-01-2012 15:30 January 6, 2012 - The Genomics in Medicine Lecture Series More: http://www.genome.gov

Read the original here:
Breast Cancer Genes, Risk Assessment and Screening - Lawrence Brody - Video

Recommendation and review posted by Bethany Smith

Discovery could lead to personalised medicine where stroke treatments are tailored to individual patients

By Claire Bates

Last updated at 9:19 AM on 6th February 2012

A single genetic mutation can double your risk of stroke, according to a new study.

Researchers found the gene variant increased the risk of large artery ischemic strokes, which account for over a third of all cases.

The discovery may lead to screening tests to identify those at risk along with earlier treatments and could potentially save thousands of lives.

Impact: Around 110,000 people in England have a stroke every year, while 300,000 people are living with resulting disabilities

Stroke is the second leading cause of death worldwide and a major cause of chronic disability in developed countries. The condition costs the NHS ?2.8billion a year.

One of the most common types is when blood flow is impaired because of a blockage to one or more of the large arteries supplying blood to the brain, known as large artery ischemic stroke.

Researchers from St George's, University of London and Oxford University compared the genetic make-up of 10,000 people who had suffered from a stroke with 40,000 healthy individuals. The study was funded by the Wellcome Trust.

They found that an alteration in a gene called HDAC9 occurs on about 10 per cent of human chromosomes. Those people who carry two copies of the variant (one inherited from each parent) have nearly twice the risk for this type of stroke compared to those with no copies of the variant. 

The protein produced by HDAC9 is already known to play a role in the formation of muscle tissue and heart development. However, the exact mechanism by which the genetic variant increases the risk of stroke is not yet known.

Professor Hugh Markus, from St George's, University of London, who co-led the study says: 'This discovery identifies a completely new mechanism for causing stroke. The next step is to determine in more detail the relationship between HDAC9 and stroke and see whether we can develop new treatments that reduce the risk of stroke.

'Interestingly, there are already drugs available which inhibit the HDAC9 protein. However, it is important that we understand the mechanism involved before trialling the effects of these drugs on stroke.'

The researchers went on to show that the new variant does not have the same effect on the risk of other types of stroke which include bleeding in the brain.

Professor Peter Donnelly, Director of the Wellcome Trust Centre for Human Genetics in the University of Oxford, who co-led the study, says: 'This is really fascinating, and if it holds up more generally, will move us closer to personalised medicine, where treatments and preventions can be tailored more precisely to individual patients.'

The study was published online in Nature Genetics today.

See the rest here:
Single genetic mutation can double your risk of stroke - but scientists hope it could lead to tailored treatments

Recommendation and review posted by Bethany Smith

SALT LAKE CITY, Feb. 6, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN - News) announced today that Jim Evans, Chief Financial Officer, is scheduled to present at the Leerink Swann 2012 Global Healthcare Conference, at 11:00 a.m. Eastern Time on Thursday, February 16, 2012. The conference is being held at the Waldorf Astoria Hotel in New York, New York.

The presentation will be available to interested parties through a live webcast accessible on the investor relations section of Myriad's website at http://www.myriad.com.

About Myriad Genetics

Myriad Genetics, Inc. (Nasdaq:MYGN - News) is a leading molecular diagnostic company dedicated to developing and marketing transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess a patient's risk of disease progression and disease recurrence. Myriad's portfolio of nine molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a focus on improving an individual's decision making process for monitoring and treating disease. With fiscal year 2011 annual revenue of over $400 million and more than 1,000 employees, Myriad is working on strategic directives, including new product introductions, companion diagnostics, and international expansion, to take advantage of significant growth opportunities. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

More:
Myriad Genetics to Present at the Leerink Swann 2012 Global Healthcare Conference

Recommendation and review posted by Bethany Smith

LOS ANGELES--(BUSINESS WIRE)--

Response Genetics, Inc. (Nasdaq: RGDX - News), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today that Thomas Bologna, CEO and Chairman, and David O’Toole, vice president and CFO, will present at the 22nd Annual UBS Global Healthcare Services Conference at the Grand Hyatt in New York.

Response Genetics’ presentation is scheduled to begin at 3:30 p.m. ET on Tuesday, February 7. A live webcast of the presentation will be available on the conference section of the company's website at http://investor.responsegenetics.com/phoenix.zhtml?c=207260&p=irol-presentations. The webcast will be archived for 60 days.

About Response Genetics, Inc.

Response Genetics Inc. (“RGI”) is focused on the development and sale of molecular diagnostic tests for cancer. RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, the Company generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. RGI was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company to successfully present at the UBS Global Healthcare Services Conference, and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions.

These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Here is the original post:
Response Genetics to Present at the 22nd Annual UBS Global Healthcare Services Conference

Recommendation and review posted by Bethany Smith

07-11-2011 15:39 http://www.StemCellTreatment.org Salima had stem cell treatment for Fibromyalgia and had very good results. We have had great success with stem cell therapy for Fibromyalgia also known as FMS. Fibromyalgia symptoms include pain and tenderness in the joints, muscles and other soft tissue. Stem cell treatment for fibromyalgia is something that ASCAAC specializes in. Go to our website for more information and fill out the form or give us a call so we can answer your stem cell and fibromyalgia questions!

View original post here:
Stem Cell Treatment Fibromyalgia - Video

Recommendation and review posted by simmons

20-12-2011 09:01 If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.

Read the original post:
Adult Stem Cell Treatments for COPD -Real patient results, USA Stem Cells- Donald W. Testimonial - Video

Recommendation and review posted by simmons

10-01-2012 17:54 Cell-based therapy research at Swedish Heart and Vascular Institute is quintessential to medical advancement. Medical director Dr. Paul P. Huang researches stem cell therapy pertaining to cardiovascular disease. He provides an historical perspective of stem cell research and explains how stem cells can help cardiovascular patients avoid surgery and improve their quality of life. Dr. Huang believes that regenerative medicine is medicine's next frontier. For more information visit http://www.swedish.org

Go here to read the rest:
Cell-based Therapy Research - Video

Recommendation and review posted by simmons

12-01-2012 07:24 If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.

Excerpt from:
Adult Stem Cell Treatments for COPD -Real patient results, USA Stem Cells- Leon B. Testimonial - Video

Recommendation and review posted by simmons

TORONTO, Feb. 6, 2012 (GLOBE NEWSWIRE) -- GeneNews Limited (TSX:GEN.TO - News), a molecular diagnostics company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has signed a memorandum of understanding ("MOU") with Shanghai Biochip Co. Ltd. ("SBC"), a leading Chinese engineering centre for advanced microarray and gene expression profiling technologies, to enter into a strategic alliance to establish the first Sentinel Centre for Personalized Medicine in China.

GeneNews and SBC would jointly establish and manage the Sentinel Centre for Personalized Medicine to co-develop and commercialize additional products based on GeneNews' proprietary platform technology, the Sentinel Principle(R). In addition, the MOU sets forth the main criteria to be incorporated into definitive development, distribution and license terms under which SBC would obtain non-exclusive rights to market and sell GeneNews' ColonSentry(TM) test in China. A formal agreement will be negotiated and executed before the end of the Company's third fiscal quarter. Financial terms were not disclosed.

"We are focused on bringing leading edge technologies to the people of China to improve healthcare outcomes," stated Dr. Yuchen Chen, Director, Business Development of SBC. "We are looking forward to working with GeneNews to establish the world's first Sentinel Centre for Personalized Medicine to advance the development and commercialization of innovative, non-invasive tests targeted at early disease detection in China."

"Shanghai Biochip's expertise in gene expression profiling platforms and well-established clinical network provide a strong foundation for us to jointly establish a state-of-the-art research and development core capability in China that is aligned with our pipeline development and commercialization objectives. We look forward to building a successful strategic alliance with Shanghai Biochip," said Gailina J. Liew, President & Chief Operating Officer of GeneNews.

The Sentinel Principle(R), a platform technology discovered and developed by GeneNews, is based on the concept that all clinical conditions and body states, including those resulting from disease or in response to treatment, generate characteristic gene expression signatures in the blood as a result of the constant and dynamic physiological interaction of blood with the cells, tissues and organs of the human body. This technology is the basis of GeneNews' initial product, ColonSentry(TM), the world's first blood test for colorectal cancer, and the SentinelGx(TM) suite of services. GeneNews' broad global patent portfolio includes issued foundational patents and pending patents in diverse disease areas such as cancer, cardiovascular, neurological and inflammatory conditions.

About Shanghai Biochip

Shanghai Biochip is a national engineering centre for advanced microarray and gene expression profiling technologies in China that has developed a strong network of academic, clinical and medical partners to utilize its expertise and services as a contract research organization and bio-banking facility.

About GeneNews

GeneNews is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management based on disease-specific biomarkers. The Company has a patented core platform technology, the Sentinel Principle(R), which has the power to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(R) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' lead product, ColonSentry(TM), is the world's first blood test to pre-screen and assess an individual's current risk for colorectal cancer. For more information on GeneNews and ColonSentry(TM), go to http://www.GeneNews.com or http://www.ColonSentry.com.

Forward-Looking Statements

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

More here:
GeneNews Enters Into MOU With Shanghai Biochip to Establish First Sentinel Centre for Personalized Medicine

Recommendation and review posted by sam

A former Sweet Home High School athlete who nearly died after a college pole vaulting accident in 2007 is being treated for a serious spinal cord injury at St. Charles Medical Center in Bend.

Keegan Burnett, 27, who now lives in Albany, is paralyzed from the waist down after a night skiing accident at Hoodoo Ski Area on Jan. 28. He is the son of Rick and Alice Burnett and a 2002 Sweet Home graduate.

“Keegan was skiing Saturday night with friends and the accident occurred when he tried to make a jump,” his mother said. “He said he made the jump twice before.”

Doctors told the Burnetts that Keegan “folded himself in half and landed on his head.”

“It completely blew out his T12 vertebrae and ruptured the C4 and C5 vertebrae,” his mother said.

The accident happened about 9 p.m. and Keegan was taken to St. Charles Medical Center by ambulance.

He had surgery Sunday, his mother said, and doctors installed a “cage” around the T12 vertebrae and cleaned up the others.

“His spinal cord was not severed, but it was severely crushed,” Burnett said. “The doctor said it is highly unlikely that Keegan will ever be able to walk again. It’s a miracle that he’s alive.”

Burnett said doctors are especially concerned about a concussion Keegan suffered, and he had CAT scans to determine if there was any brain swelling every day for the first three or four days he was in the hospital.

Back in May 2007, Keegan suffered a traumatic head injury while pole vaulting for the Idaho State University Bengals track team during a meet in Utah. Coming down, he struck his head on concrete that had not been covered with a protective mat. A portion of his skull had to be removed due to swelling of his brain. Keegan was in the intensive care unit at McKay-Dee Hospital for weeks and lost more than 35 pounds.

“Because of the previous injury, Keegan reacts differently than other people and the severity of a concussion is much more severe,” his mother said.

After healing, Keegan completed a degree in human physiology from the University of Oregon in 2008.

“He recently applied to graduate schools in human physiology at the UO, Oregon State and Arizona,” Burnett said. “He just got a temporary job at Entek in Lebanon and had worked one day before the accident.”

Daily updates about Keegan can be found at http://www.caringbridge.org/visit/keeganburnett.

Originally posted here:
Young athlete suffers second serious injury

Recommendation and review posted by sam

29-01-2012 23:26 Fourteen patients were randomized to see if adipose-derived adult stem cells would help limit the damage from an acute heart attack. Infarct size was decreased by 50%, the perfusion defect was 17% smaller, and the left ventriclular ejection fraction was increased about 6% better than the control group. Stem cell vocabulary was reviewed and highlighted that there are embryonic stem cells and adult stem cells and that sources of stem cell are from bone marrow, adipose tissue, blood, umbilical cord blood and from cloned embryonic cell lines. Stem cells can develop into 200 different cell types.

Excerpt from:
Stem Cells Help Heart Attack Victims - Video

Recommendation and review posted by Bethany Smith